香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 HealthyWay Inc. 健康之路股份有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2587） 自願公告 控股股東自願延長禁售期 本 公 告 乃 由 健 康 之 路 股 份 有 限 公 司（「本公司」）自 願 發 佈，旨 在 告 知 其 股 東 及 潛 在 投 資 者，其 控 股 股 東 張 萬 能 先 生 及 由 張 萬 能 先 生 全 資 擁 有 的 豐 基 有 限 公 司 已 延 長 禁 售 期。 茲 提 述 本 公 司 日 期 為 二 零 二 四 年 十 二 月 十 八 日 的 招 股 章 程（「招股章程」） 及 本 公 司 日 期 為 二 零 二 五 年 七 月 二 日 的 公 告（「該公告」）。除 另 有 定 義 外， 本 文 所 用 詞 彙 與 招 股 章 程 所 界 定 者 ...

Core Viewpoint - The company is selling a 51% stake in Fujian Jianchen Pharmaceutical Co., Ltd. for RMB 1.6779 million due to declining performance and high fixed costs associated with its operations [1] Group 1: Company Actions - The company’s wholly-owned subsidiary, Zhejiang Health Road Technology Group Co., Ltd., is the entity involved in the sale [1] - The decision to sell the stake is driven by the need to reduce costs and improve efficiency amid disappointing financial performance [1] Group 2: Financial Performance - The company experienced a temporary revenue increase due to stockpiling of Oseltamivir during the flu outbreak at the end of 2023 [1] - Following the decline of the pandemic, the limitations of being a single-product pharmaceutical wholesaler became apparent, leading to a significant drop in revenue and net profit starting August 2024 [1] - Fixed costs related to drug procurement, storage, transportation, and employee salaries are relatively high, contributing to the decision to divest [1] Group 3: Future Plans - Proceeds from the sale will be used to develop the company’s enterprise services and digital marketing services [1]

Core Viewpoint - Health Road (02587.HK) announced the sale of a 51% stake in its subsidiary, Fujian Jianchen Pharmaceutical Co., Ltd., to Ms. Xiao Jing for a total consideration of RMB 1.6779 million, effective December 24, 2025. Following the sale, the subsidiary will no longer be part of the company's consolidated financial statements [1]. Group 1 - The sale is driven by the temporary revenue increase from stockpiling Oseltamivir during the flu outbreak at the end of 2023, which highlighted the limitations of the subsidiary as a single-product pharmaceutical wholesaler [1]. - Since August 2024, the subsidiary's performance has declined significantly due to unmet expectations from drug procurement agreements with other pharmaceutical companies, leading to a substantial drop in revenue and net profit [1]. - The company aims to use the proceeds from the sale to develop its enterprise services and digital marketing services, focusing on cost reduction and efficiency improvement [1].

Core Viewpoint - The company is selling a 51% stake in Fujian Jianchen Pharmaceutical Co., Ltd. for RMB 1.6779 million due to declining performance and high fixed costs associated with its operations [1] Group 1: Company Actions - The sale is being conducted by Zhejiang Health Road Technology Group Co., Ltd., a wholly-owned subsidiary of the company [1] - The proceeds from the sale will be used to develop the company's enterprise services and digital marketing services [1] Group 2: Financial Performance - The company experienced a temporary revenue increase due to stockpiling of Oseltamivir during the flu outbreak at the end of 2023 [1] - Following the decline of the pandemic, the limitations of being a single-product pharmaceutical wholesaler became evident, leading to a significant drop in revenue and net profit starting from August 2024 [1] - Fixed costs related to drug procurement, storage, transportation, and employee salaries are relatively high, contributing to the decision to divest [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 於本公告日期，出 售 公 司 為 本 公 司 的 間 接 非 全 資 附 屬 公 司，由 賣 方 及 買方分別持有51%及49%股 權。買 方 為 出 售 公 司 的 主 要 股 東 及 董 事；因 此，根 據 上 市 規 則 第14A.07(1)條，彼 為 本 公 司 附 屬 公 司 層 面 的 關 連 人 士。因 此，根 據 上 市 規 則 第14A章，出 售 事 項 構 成 本 公 司 的 關 連 交 易。 根據上市規則第14A.101條，由 於(1)買 方 為 附 屬 公 司 層 面 的 關 連 人 士； (2)董 事 會 已 批 准 出 售 事 項；及(3)獨立非執行董事已確認出售事項的條 款屬公平合理及出售事項按一般商業條款或更佳條款訂立且符合本 公 司 及 其 股 東 的 整 體 利 益，故 出 售 事 項 須 遵 守 上 ...

Group 1 - The core point of the article highlights that southbound funds reduced their holdings in Health Road (02587.HK) by 891,000 shares on December 22, while there were three days of net increases totaling 588,600 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings on nine occasions, resulting in a total net reduction of 503,400 shares [1] - Currently, southbound funds hold 185 million shares of Health Road, which accounts for 21.08% of the company's total issued ordinary shares [1] Group 2 - Health Road Holdings Limited primarily engages in providing enterprise services, digital marketing services, and health care services as an investment holding company [1] - The company operates its business through three segments: enterprise services and digital marketing services, health care services, and other health services and products sold through various online and offline channels [1] - The enterprise services and digital marketing services segment includes content services, information technology services, and digital marketing services, while the health care services segment focuses on medical support services and value-based medical services [1]

Core Viewpoint - Southbound funds increased their holdings in Health Road (02587.HK) by 27,600 shares on December 17, while experiencing net reductions in holdings over the past trading days [1] Group 1: Southbound Fund Activity - Over the last 5 trading days, southbound funds reduced their holdings on 3 days, with a total net reduction of 14,900 shares [1] - In the last 20 trading days, there were 10 days of reductions, totaling a net decrease of 4,331,900 shares [1] - Currently, southbound funds hold 184 million shares of Health Road, representing 20.98% of the company's issued ordinary shares [1] Group 2: Company Overview - Health Road Holdings Limited is primarily engaged in providing enterprise services, digital marketing services, and health care services as an investment holding company [1] - The company operates through three segments: enterprise services and digital marketing services, health care services, and other health services and products [1] - The enterprise services and digital marketing segment includes content services, information technology services, and digital marketing services [1] - The health care services segment provides medical support services and value-based medical services [1] - The other segment offers various health services and products through online and offline channels, including patient visitation services and nutritional supplements [1] - The company primarily conducts its business in the domestic market [1]

智通财经APP讯，健康之路(02587)发布公告，于2025年12月17日，该公司斥资41.04万港元回购9.4万股 股份，每股回购价格为4.27-4.41港元。 ...

健康之路(02587)发布公告，于2025年12月17日，该公司斥资41.04万港元回购9.4万股股份，每股回购价 格为4.27-4.41港元。 ...

格隆汇12月17日丨健康之路(02587.HK)发布公告，2025年12月17日耗资41万港元回购9.4万股，回购价 格每股4.27-4.41港元。 ...